The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2015 | Results of the ENDEAVOR trial comparing carfilzomib and bortezomib in multiple myeloma
Joseph Mikhael
• 2 Jun 2015
Dr Joseph Mikhael discusses the results of the ENDEAVOR trial, a phase 3 head-to-head study that demonstrates superiority of carfilzomib over bortezomib in patients with relapsed multiple myeloma.
